Strategy for making safer opioids bolstered.

Compounds have been made that activate only the G-protein signalling pathway when bound to the µ-opioid receptor — the target of opioid pain relievers. These compounds lack one of the main side effects of currently used opioids. Compounds have been made that activate only the G-protein signalling pathway when bound to the µ-opioid receptor — the target of opioid pain relievers. These compounds lack one of the main side effects of currently used opioids.